The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Calithera Biosciences, Inc. Common Stock 13089P101 5,290 2,426,702 SH   SOLE   2,426,702 0 0
Karyopharm Therapeutics, Inc. Common Stock 48576U106 13,170 2,263,006 SH   SOLE   2,263,006 0 0
Mereo BioPharma Group PLC ADS 589492107 621 256,734 SH   SOLE   256,734 0 0
Tandem Diabetes, Inc. Common Stock 875372203 119,380 1,000,000 SH   SOLE   1,000,000 0 0